{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:05:04Z","timestamp":1794654304415,"version":"4.9.1"},"reference-count":216,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002967"],"award-info":[{"award-number":["82002967"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972283"],"award-info":[{"award-number":["81972283"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.pharmthera.2023.108391","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T12:48:47Z","timestamp":1679489327000},"page":"108391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":323,"special_numbering":"C","title":["PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets"],"prefix":"10.1016","volume":"245","author":[{"given":"Hao","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2023.108391_bb0005","doi-asserted-by":"crossref","first-page":"G691","DOI":"10.1152\/ajpgi.00116.2014","article-title":"Activation of the renin-angiotensin system stimulates biliary hyperplasia during cholestasis induced by extrahepatic bile duct ligation","volume":"308","author":"Afroze","year":"2015","journal-title":"American Journal of Physiology. Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0010","article-title":"Endoplasmic reticulum stress in liver diseases","author":"Ajoolabady","year":"2022","journal-title":"Hepatology.2013;77(2):619-639"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0015","doi-asserted-by":"crossref","first-page":"20874","DOI":"10.1074\/jbc.M312802200","article-title":"Peroxisome proliferator-activated receptor beta\/delta regulates very low density lipoprotein production and catabolism in mice on a Western diet","volume":"279","author":"Akiyama","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0020","doi-asserted-by":"crossref","first-page":"8162421","DOI":"10.1155\/2017\/8162421","article-title":"The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications","volume":"2017","author":"Alisi","year":"2017","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0025","doi-asserted-by":"crossref","first-page":"5558731","DOI":"10.1155\/2021\/5558731","article-title":"Activation of the peroxisome proliferator-activated receptors (PPAR-alpha\/gamma) and the fatty acid metabolizing enzyme protein CPT1A by camel milk treatment counteracts the high-fat diet-induced nonalcoholic fatty liver disease","volume":"2021","author":"AlNafea","year":"2021","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0030","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1053\/j.gastro.2006.03.041","article-title":"NAFLD, obesity, and bariatric surgery","volume":"130","author":"Angulo","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0035","doi-asserted-by":"crossref","first-page":"30614","DOI":"10.1074\/jbc.M304654200","article-title":"Peroxisome proliferator-activated receptor-gamma represses GLUT4 promoter activity in primary adipocytes, and rosiglitazone alleviates this effect","volume":"278","author":"Armoni","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0040","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jhep.2009.03.008","article-title":"Kupffer cells in non-alcoholic fatty liver disease: The emerging view","volume":"51","author":"Baffy","year":"2009","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature13887","article-title":"An ERK\/Cdk5 axis controls the diabetogenic actions of PPARgamma","volume":"517","author":"Banks","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0050","article-title":"Lipid peroxidation-derived aldehydes, 4-hydroxynonenal and malondialdehyde in aging-related disorders","volume":"7","author":"Barrera","year":"2018","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/ATVBAHA.107.148817","article-title":"Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?","volume":"28","author":"Barter","year":"2008","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0060","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2016.05.037","article-title":"Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions","volume":"65","author":"Beattie","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0065","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0070","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/90992","article-title":"The adipocyte-secreted protein Acrp30 enhances hepatic insulin action","volume":"7","author":"Berg","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/wsbm.1499","article-title":"Liver fibrosis: Pathophysiology and clinical implications","volume":"13","author":"Berumen","year":"2021","journal-title":"WIREs Mechanisms of Disease"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tcb.2015.12.002","article-title":"TNF and ROS crosstalk in inflammation","volume":"26","author":"Blaser","year":"2016","journal-title":"Trends in Cell Biology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0085","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041197","article-title":"PPAR agonists and metabolic syndrome: An established role?","volume":"19","author":"Botta","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0095","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) alpha\/gamma\/delta triple activators: Discovery of lanifibranor, a new antifibrotic clinical candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105739","article-title":"Hepatic stellate cells role in the course of metabolic disorders development - A molecular overview","volume":"170","author":"Bourebaba","year":"2021","journal-title":"Pharmacological Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0105","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3389\/fimmu.2015.00602","article-title":"Macrophages during the fibrotic process: M2 as friend and foe","volume":"6","author":"Braga","year":"2015","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0115","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/hep.21429","article-title":"Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis","volume":"44","author":"Bugianesi","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0120","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.20920","article-title":"Insulin resistance: A metabolic pathway to chronic liver disease","volume":"42","author":"Bugianesi","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0125","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1210\/jc.2004-2240","article-title":"Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity","volume":"90","author":"Bugianesi","year":"2005","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0130","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/eci.12052","article-title":"Sfrp5 correlates with insulin resistance and oxidative stress","volume":"43","author":"Carstensen","year":"2013","journal-title":"European Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0135","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0140","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2009.05.036","article-title":"Identification of a physiologically relevant endogenous ligand for PPARalpha in liver","volume":"138","author":"Chakravarthy","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0145","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0150","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1210\/endo.135.2.8033830","article-title":"Peroxisome proliferator-activated receptor (PPAR) gamma: Adipose-predominant expression and induction early in adipocyte differentiation","volume":"135","author":"Chawla","year":"1994","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0155","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41401-021-00836-9","article-title":"GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis","volume":"43","author":"Chen","year":"2022","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radical Biology & Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0165","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1164\/rccm.200907-1047OC","article-title":"Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice","volume":"182","author":"Cho","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0175","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature10383","article-title":"Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation","volume":"477","author":"Choi","year":"2011","journal-title":"Nature"},{"issue":"575-594","key":"10.1016\/j.pharmthera.2023.108391_bb0180","first-page":"ix","article-title":"Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease","volume":"8","author":"Choudhury","year":"2004","journal-title":"Clinics in Liver Disease"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0185","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1161\/CIRCRESAHA.108.188771","article-title":"Age-accelerated atherosclerosis correlates with failure to upregulate antioxidant genes","volume":"104","author":"Collins","year":"2009","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0190","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0195","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0200","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3233\/CBM-170157","article-title":"Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study","volume":"20","author":"Deng","year":"2017","journal-title":"Cancer Biomarkers"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0205","first-page":"649","article-title":"Peroxisome proliferator-activated receptors: Nuclear control of metabolism","volume":"20","author":"Desvergne","year":"1999","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030695","article-title":"ER stress responses: An emerging modulator for innate immunity","volume":"9","author":"Di Conza","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/j.2040-4603.2013.tb00510.x","article-title":"Kupffer cells in the liver","volume":"3","author":"Dixon","year":"2013","journal-title":"Comprehensive Physiology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0220","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0225","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1161\/CIRCRESAHA.107.164384","article-title":"Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature","volume":"102","author":"Duan","year":"2008","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0230","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/984578","article-title":"How inflammation impinges on NAFLD: A role for Kupffer cells","volume":"2015","author":"Duarte","year":"2015","journal-title":"BioMed Research International"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0235","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.cell.2011.11.062","article-title":"Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones","volume":"148","author":"Dutchak","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0240","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41418-020-00671-1","article-title":"Hepatocyte-specific deletion of XBP1 sensitizes mice to liver injury through hyperactivation of IRE1alpha","volume":"28","author":"Duwaerts","year":"2021","journal-title":"Cell Death and Differentiation"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0245","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0255","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2174\/092986711796504600","article-title":"Anti-inflammatory and antioxidant properties of a new arylidene-thiazolidinedione in macrophages","volume":"18","author":"Faine","year":"2011","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0260","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11010-013-1694-7","article-title":"Endoplasmic reticulum stress leads to lipid accumulation through upregulation of SREBP-1c in normal hepatic and hepatoma cells","volume":"381","author":"Fang","year":"2013","journal-title":"Molecular and Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0265","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bcp.2014.03.016","article-title":"Chrysin attenuates inflammation by regulating M1\/M2 status via activating PPARgamma","volume":"89","author":"Feng","year":"2014","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0270","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.coph.2006.06.009","article-title":"PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome","volume":"6","author":"Fievet","year":"2006","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0275","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1073\/pnas.94.9.4312","article-title":"Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta","volume":"94","author":"Forman","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: The role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0285","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPARalpha gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0290","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0295","doi-asserted-by":"crossref","first-page":"45888","DOI":"10.1074\/jbc.M105490200","article-title":"Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3","volume":"276","author":"Fu","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0300","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/hep.23094","article-title":"Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis","volume":"50","author":"Fujita","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0305","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.23116","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","volume":"50","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0310","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-gamma-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0315","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0320","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-alpha\/gamma agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0325","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1734-1140(10)70262-0","article-title":"COX-2 as a target for cancer chemotherapy","volume":"62","author":"Ghosh","year":"2010","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0330","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature13989","article-title":"Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors","volume":"518","author":"Gomez Perdiguero","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0335","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1475-2891-13-17","article-title":"Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications--a review","volume":"13","author":"Grygiel-Gorniak","year":"2014","journal-title":"Nutrition Journal"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0340","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep4.1356","article-title":"Liver macrophages: Old Dogmas and new insights","volume":"3","author":"Guillot","year":"2019","journal-title":"Hepatology Communications"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0345","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0350","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ebiom.2017.10.027","article-title":"Metabolomics and gene expression analysis reveal down-regulation of the citric acid (TCA) cycle in non-diabetic CKD patients","volume":"26","author":"Hallan","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0355","series-title":"Free radicals in biology and medicine","author":"Halliwell","year":"2015"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0360","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2337\/db07-0972","article-title":"Therapeutic potential of peroxisome proliferators--activated receptor-alpha\/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes","volume":"57","author":"Han","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0365","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2217\/fca-2017-0019","article-title":"PPARs: Regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-beta\/delta and PPAR-gamma","volume":"13","author":"Han","year":"2017","journal-title":"Future Cardiology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0370","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2337\/diabetes.55.01.06.db05-0648","article-title":"Muraglitazar, a novel dual (alpha\/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db\/db mice","volume":"55","author":"Harrity","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0375","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1074\/jbc.M310284200","article-title":"Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells","volume":"279","author":"Hazra","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105816","article-title":"Docosahexaenoic acid inhibits hepatic stellate cell activation to attenuate liver fibrosis in a PPARgamma-dependent manner","volume":"75","author":"He","year":"2019","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0385","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00775-021-01874-8","article-title":"Bis(ethylmaltolato)oxidovanadium (IV) alleviates neuronal apoptosis through regulating peroxisome proliferator-activated receptor gamma in a triple transgenic animal model of Alzheimer's disease","volume":"26","author":"He","year":"2021","journal-title":"Journal of Biological Inorganic Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0390","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00125-013-3145-0","article-title":"Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus","volume":"57","author":"Hogan","year":"2014","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082189","article-title":"The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development","volume":"19","author":"Hong","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0400","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.metabol.2010.09.007","article-title":"Increased adipose tissue lipolysis after a 2-week high-fat diet in sedentary overweight\/obese men","volume":"60","author":"Howe","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0405","first-page":"6483","article-title":"High expression of active ATF6 aggravates endoplasmic reticulum stress-induced vascular endothelial cell apoptosis through the mitochondrial apoptotic pathway","volume":"17","author":"Huang","year":"2018","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0410","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0415","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108298","article-title":"PPARgamma signaling in hepatocarcinogenesis: Mechanistic insights for cellular reprogramming and therapeutic implications","volume":"240","author":"Ishtiaq","year":"2022","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0425","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPARalpha\/gamma agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver International"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0430","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3748\/wjg.14.22","article-title":"Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease","volume":"14","author":"Kallwitz","year":"2008","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0435","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","article-title":"Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet","volume":"315","author":"Kawaguchi","year":"2004","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0440","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ni1018","article-title":"Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-gamma and RelA","volume":"5","author":"Kelly","year":"2004","journal-title":"Nature Immunology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0445","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.biochi.2016.12.019","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","volume":"136","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0450","doi-asserted-by":"crossref","first-page":"522","DOI":"10.21037\/hbsn.2019.05.08","article-title":"Overview of emerging treatment of non-alcoholic fatty liver disease: More than one drug needed?","volume":"8","author":"Kim","year":"2019","journal-title":"Hepatobiliary Surgery and Nutrition"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0455","doi-asserted-by":"crossref","first-page":"H1647","DOI":"10.1152\/ajpheart.00148.2009","article-title":"Disruption of endothelial peroxisome proliferator-activated receptor-gamma reduces vascular nitric oxide production","volume":"297","author":"Kleinhenz","year":"2009","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0460","doi-asserted-by":"crossref","first-page":"254S","DOI":"10.3945\/ajcn.2009.28449B","article-title":"Fibroblast growth factor 21: From pharmacology to physiology","volume":"91","author":"Kliewer","year":"2010","journal-title":"The American Journal of Clinical Nutrition"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0465","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.cca.2011.04.013","article-title":"The role of oxidative stress in non-alcoholic steatohepatitis","volume":"412","author":"Koek","year":"2011","journal-title":"Clinica Chimica Acta"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0470","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3350\/cmh.2013.19.3.210","article-title":"Nonalcoholic fatty liver disease: Molecular mechanisms for the hepatic steatosis","volume":"19","author":"Koo","year":"2013","journal-title":"Clinical and Molecular Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0475","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0480","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR alpha\/gamma agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0485","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1096\/fj.11-189472","article-title":"Kupffer cell depletion prevents but has no therapeutic effect on metabolic and inflammatory changes induced by a high-fat diet","volume":"25","author":"Lanthier","year":"2011","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0490","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/gut.2005.079194","article-title":"Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats","volume":"55","author":"Leclercq","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0495","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.3390\/nu6083303","article-title":"Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition","volume":"6","author":"Lee","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0500","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/MCB.15.6.3012","article-title":"Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators","volume":"15","author":"Lee","year":"1995","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0505","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3892\/ijmm.2016.2531","article-title":"5,7-Dihydroxy-6-geranylflavanone improves insulin sensitivity through PPARalpha\/gamma dual activation","volume":"37","author":"Lee","year":"2016","journal-title":"International Journal of Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0510","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/271983","article-title":"Peroxisome proliferator-activated receptors and the heart: Lessons from the past and future directions","volume":"2015","author":"Lee","year":"2015","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0515","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/joim.13380","article-title":"Inflammatory and fibrotic mechanisms in NAFLD-implications for new treatment strategies","volume":"291","author":"Lee","year":"2022","journal-title":"Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0520","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","article-title":"Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism","volume":"1","author":"Lefere","year":"2019","journal-title":"JHEP Reports"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0525","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/hepr.12244","article-title":"Hepatic molecular effects of rosiglitazone in human non-alcoholic steatohepatitis suggest long-term pro-inflammatory damage","volume":"44","author":"Lemoine","year":"2014","journal-title":"Hepatology Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0530","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.yexcr.2018.06.033","article-title":"Rosiglitazone rescues human neural stem cells from amyloid-beta induced ER stress via PPARgamma dependent signaling","volume":"370","author":"Lin","year":"2018","journal-title":"Experimental Cell Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0535","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1124\/jpet.107.129122","article-title":"Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: Modulation by the 5-aminosalicylic acid agonist","volume":"324","author":"Linard","year":"2008","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0540","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2014.3321","article-title":"Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: The AleCardio randomized clinical trial","volume":"311","author":"Lincoff","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0545","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0550","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.5713\/ajas.15.0674","article-title":"Peripheral insulin doesn't alter appetite of broiler chicks","volume":"29","author":"Liu","year":"2016","journal-title":"Asian-Australasian Journal of Animal Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0555","article-title":"Chronic inflammation in non-alcoholic steatohepatitis: Molecular mechanisms and therapeutic strategies","volume":"11","author":"Luci","year":"2020","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0560","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-gamma activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0565","article-title":"Peroxisome proliferator-activated receptor-gamma reduces ER stress and inflammation via targeting NGBR expression","volume":"12","author":"Ma","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0570","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.lfs.2013.10.022","article-title":"Harnessing the benefits of PPARbeta\/delta agonists","volume":"93","author":"Mackenzie","year":"2013","journal-title":"Life Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0575","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064258","article-title":"Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice","volume":"8","author":"Magliano","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0580","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: A feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0585","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0590","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1101\/gad.14.6.627","article-title":"Controlling TGF-beta signaling","volume":"14","author":"Massague","year":"2000","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0595","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0600","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik","year":"2006","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0605","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158298","article-title":"PPARs as metabolic sensors and therapeutic targets in liver diseases","volume":"22","author":"Monroy-Ramirez","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0610","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0615","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1017\/S0029665119000570","article-title":"From sugar to liver fat and public health: Systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis","volume":"78","author":"Moore","year":"2019","journal-title":"The Proceedings of the Nutrition Society"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0620","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1096\/fj.10-173716","article-title":"Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts","volume":"25","author":"Moran-Salvador","year":"2011","journal-title":"The FASEB Journal"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0625","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPARgamma deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Moran-Salvador","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0630","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/cr.2010.178","article-title":"Crosstalk of reactive oxygen species and NF-kappaB signaling","volume":"21","author":"Morgan","year":"2011","journal-title":"Cell Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20081386","article-title":"How mitochondria produce reactive oxygen species","volume":"417","author":"Murphy","year":"2009","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0640","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: Nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0645","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: A meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Internal Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0650","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/00365520802530861","article-title":"Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice","volume":"44","author":"Nan","year":"2009","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0655","first-page":"1008","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0660","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbrc.2009.05.070","article-title":"Critical role of Kupffer cells in the management of diet-induced diabetes and obesity","volume":"385","author":"Neyrinck","year":"2009","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0665","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0670","series-title":"Molecular and Cellular Regulation of Adaptation to Exercise","first-page":"39","article-title":"Exercise and regulation of lipid metabolism","author":"Noland","year":"2015"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083899","article-title":"Nonalcoholic fatty liver disease: Focus on new biomarkers and lifestyle interventions","volume":"22","author":"Notarnicola","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0680","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0685","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1530\/eje.1.01821","article-title":"Plasma adiponectin is decreased in nonalcoholic fatty liver disease","volume":"152","author":"Pagano","year":"2005","journal-title":"European Journal of Endocrinology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0690","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to pioglitazone 45 mg in diabetic dyslipidemia (PRESS V)","volume":"8","author":"Pai","year":"2014","journal-title":"Journal of Diabetes Science and Technology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0695","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/jn\/136.12.3022","article-title":"Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome","volume":"136","author":"Palmieri","year":"2006","journal-title":"The Journal of Nutrition"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0700","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1158\/0008-5472.CAN-03-3924","article-title":"Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer","volume":"64","author":"Park","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0705","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.niox.2010.04.007","article-title":"Regulation of the expression of inducible nitric oxide synthase","volume":"23","author":"Pautz","year":"2010","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0710","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/hep.27297","article-title":"The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice","volume":"60","author":"Pawlak","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0715","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","article-title":"Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits","volume":"77","author":"Peiseler","year":"2022","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0720","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI119715","article-title":"Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling","volume":"100","author":"Peraldi","year":"1997","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0725","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature13478","article-title":"The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes","volume":"510","author":"Perry","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0730","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0735","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0740","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/01.ATV.0000177805.65864.d4","article-title":"Peroxisome proliferator-activated receptor gamma ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor gamma-dependent mechanisms","volume":"25","author":"Polikandriotis","year":"2005","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0745","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1021\/jo4001433","article-title":"A perspective on free radical autoxidation: The physical organic chemistry of polyunsaturated fatty acid and sterol peroxidation","volume":"78","author":"Porter","year":"2013","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0750","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/hep.23270","article-title":"Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial","volume":"51","author":"Ratziu","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0755","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","article-title":"Breakthroughs in therapies for NASH and remaining challenges","volume":"76","author":"Ratziu","year":"2022","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0760","doi-asserted-by":"crossref","first-page":"14751","DOI":"10.1073\/pnas.95.25.14751","article-title":"Thiazolidinediones and insulin resistance: Peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene","volume":"95","author":"Ribon","year":"1998","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0765","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0770","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/hep.24553","article-title":"Dysregulation of the unfolded protein response in db\/db mice with diet-induced steatohepatitis","volume":"54","author":"Rinella","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0775","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2174\/1566524016666160523143937","article-title":"The role of the PERK\/eIF2alpha\/ATF4\/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress","volume":"16","author":"Rozpedek","year":"2016","journal-title":"Current Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0780","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1006\/bbrc.2000.3868","article-title":"Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone","volume":"278","author":"Sakamoto","year":"2000","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0785","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1152\/physiolgenomics.00127.2009","article-title":"Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta\/delta in regulation of gene expression in mouse liver","volume":"41","author":"Sanderson","year":"2010","journal-title":"Physiological Genomics"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0790","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0795","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","article-title":"PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene","volume":"15","author":"Schoonjans","year":"1996","journal-title":"The EMBO Journal"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0800","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1074\/jbc.M410078200","article-title":"Adipogenic transcriptional regulation of hepatic stellate cells","volume":"280","author":"She","year":"2005","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0805","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diabetes.55.03.06.db05-0841","article-title":"Overexpression of suppressor of cytokine signaling 3 in adipose tissue causes local but not systemic insulin resistance","volume":"55","author":"Shi","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0810","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0815","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1007\/s00018-018-2838-4","article-title":"Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation","volume":"75","author":"Silva","year":"2018","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0820","doi-asserted-by":"crossref","first-page":"re3","DOI":"10.1126\/scisignal.272re3","article-title":"CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior","volume":"2","author":"Silverstein","year":"2009","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0825","first-page":"705","article-title":"Roles of endoplasmic reticulum stress in immune responses","volume":"41","author":"So","year":"2018","journal-title":"Molecules and Cells"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0830","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1007\/s10620-016-4054-0","article-title":"Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease","volume":"61","author":"Softic","year":"2016","journal-title":"Digestive Diseases and Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0835","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/j.1572-0241.2000.02046.x","article-title":"Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis","volume":"95","author":"Sonsuz","year":"2000","journal-title":"The American Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0840","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35053000","article-title":"The hormone resistin links obesity to diabetes","volume":"409","author":"Steppan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0845","doi-asserted-by":"crossref","first-page":"95974","DOI":"10.1155\/2007\/95974","article-title":"PPARs, obesity, and inflammation","volume":"2007","author":"Stienstra","year":"2007","journal-title":"PPAR Research"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0850","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1083\/jcb.201906047","article-title":"Protein quality control in the secretory pathway","volume":"218","author":"Sun","year":"2019","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0855","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/509057","article-title":"Genistein attenuates nonalcoholic steatohepatitis and increases hepatic PPARgamma in a rat model","volume":"2015","author":"Susutlertpanya","year":"2015","journal-title":"Evidence-based Complementary and Alternative Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0860","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.pharmthera.2017.05.011","article-title":"Targeting nuclear receptors for the treatment of fatty liver disease","volume":"179","author":"Tanaka","year":"2017","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0865","doi-asserted-by":"crossref","first-page":"15924","DOI":"10.1073\/pnas.0306981100","article-title":"Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome","volume":"100","author":"Tanaka","year":"2003","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0870","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1152\/physrev.00019.2009","article-title":"Metabolic effects of fructose and the worldwide increase in obesity","volume":"90","author":"Tappy","year":"2010","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0875","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: Revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0880","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0885","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1128\/MCB.15.1.351","article-title":"PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene","volume":"15","author":"Tontonoz","year":"1995","journal-title":"Molecular and Cellular Biology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0890","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1101\/gad.8.10.1224","article-title":"mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer","volume":"8","author":"Tontonoz","year":"1994","journal-title":"Genes & Development"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0895","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0092-8674(94)90006-X","article-title":"Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor","volume":"79","author":"Tontonoz","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0900","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev.biochem.77.061307.091829","article-title":"Fat and beyond: The diverse biology of PPARgamma","volume":"77","author":"Tontonoz","year":"2008","journal-title":"Annual Review of Biochemistry"},{"issue":"627-640","key":"10.1016\/j.pharmthera.2023.108391_bb0905","article-title":"Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0910","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jhep.2015.02.039","article-title":"Hepatic fibrosis: Concept to treatment","volume":"62","author":"Trautwein","year":"2015","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0915","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","article-title":"Mechanisms of hepatic stellate cell activation","volume":"14","author":"Tsuchida","year":"2017","journal-title":"Nature Reviews. Gastroenterology & Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0920","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0140-6736(98)10364-1","article-title":"Medical significance of peroxisome proliferator-activated receptors","volume":"354","author":"Vamecq","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0925","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bbrc.2007.12.088","article-title":"PPARgamma-dependent and -independent effects of rosiglitazone on lipotoxic human pancreatic islets","volume":"366","author":"Vandewalle","year":"2008","journal-title":"Biochemical and Biophysical Research Communications"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0930","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.biochi.2017.07.003","article-title":"Anti-obesogenic effects of WY14643 (PPAR-alpha agonist): Hepatic mitochondrial enhancement and suppressed lipogenic pathway in diet-induced obese mice","volume":"140","author":"Veiga","year":"2017","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0935","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0940","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.26607","article-title":"M2 Kupffer cells promote M1 Kupffer cell apoptosis: A protective mechanism against alcoholic and nonalcoholic fatty liver disease","volume":"59","author":"Wan","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0945","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0929-6646(09)60202-3","article-title":"Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease","volume":"105","author":"Wang","year":"2006","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0950","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(03)00269-1","article-title":"Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity","volume":"113","author":"Wang","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0955","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mam.2018.06.003","article-title":"Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications","volume":"65","author":"Weiskirchen","year":"2019","journal-title":"Molecular Aspects of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0960","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1042\/BJ20140881","article-title":"Steatosis inhibits liver cell store-operated Ca(2)(+) entry and reduces ER Ca(2)(+) through a protein kinase C-dependent mechanism","volume":"466","author":"Wilson","year":"2015","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0965","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0970","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1074\/jbc.275.3.1873","article-title":"A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation","volume":"275","author":"Wright","year":"2000","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0975","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/JCI1244","article-title":"PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C\/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes","volume":"101","author":"Wu","year":"1998","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0980","doi-asserted-by":"crossref","DOI":"10.3390\/cells7120270","article-title":"Protective effects and target network analysis of ginsenoside Rg1 in cerebral ischemia and reperfusion injury: A comprehensive overview of experimental studies","volume":"7","author":"Xie","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110155","article-title":"Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-gamma and PPAR-alpha","volume":"127","author":"Xie","year":"2020","journal-title":"Biomedicine & Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0990","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1136\/gut.2007.129858","article-title":"Synergistic effects of RXR alpha and PPAR gamma ligands to inhibit growth in human colon cancer cells--phosphorylated RXR alpha is a critical target for colon cancer management","volume":"56","author":"Yamazaki","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.pharmthera.2023.108391_bb0995","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.apsb.2019.11.017","article-title":"Herbal drug discovery for the treatment of nonalcoholic fatty liver disease","volume":"10","author":"Yan","year":"2020","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1000","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/brv.12667","article-title":"Evaluating endoplasmic reticulum stress and unfolded protein response through the lens of ecology and evolution","volume":"96","author":"Yap","year":"2021","journal-title":"Biological Reviews of the Cambridge Philosophical Society"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1005","doi-asserted-by":"crossref","first-page":"E531","DOI":"10.1152\/ajpendo.00299.2002","article-title":"PPARalpha \/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly","volume":"284","author":"Ye","year":"2003","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1010","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1015","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.biocel.2010.02.006","article-title":"Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro","volume":"42","author":"Yu","year":"2010","journal-title":"The International Journal of Biochemistry & Cell Biology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020274","article-title":"Endoplasmic reticulum stress impaired uncoupling protein 1 expression via the suppression of peroxisome proliferator-activated receptor gamma binding activity in mice beige adipocytes","volume":"20","author":"Yuliana","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","article-title":"Hepatic regulation of VLDL receptor by PPARbeta\/delta and FGF21 modulates non-alcoholic fatty liver disease","volume":"8","author":"Zarei","year":"2018","journal-title":"Molecular Metabolism"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.gene.2017.10.066","article-title":"SFRP5 is a target gene transcriptionally regulated by PPARgamma in 3T3-L1 adipocytes","volume":"641","author":"Zeng","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00018-012-1046-x","article-title":"Peroxisome proliferator-activated receptor-gamma as a therapeutic target for hepatic fibrosis: From bench to bedside","volume":"70","author":"Zhang","year":"2013","journal-title":"Cellular and Molecular Life Sciences"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1040","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12463","article-title":"PPARgamma attenuates hepatic inflammation and oxidative stress of nonalcoholic steatohepatitis via modulating the miR215p\/SFRP5 pathway","volume":"24","author":"Zhang","year":"2021","journal-title":"Molecular Medicine Reports"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1045","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3748\/wjg.v20.i7.1768","article-title":"Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Zhang","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1050","doi-asserted-by":"crossref","first-page":"37603","DOI":"10.1074\/jbc.M604709200","article-title":"Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis","volume":"281","author":"Zhang","year":"2006","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1055","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.intimp.2018.03.036","article-title":"Micheliolide alleviates hepatic steatosis in db\/db mice by inhibiting inflammation and promoting autophagy via PPAR-gamma-mediated NF-small ka, CyrillicB and AMPK\/mTOR signaling","volume":"59","author":"Zhong","year":"2018","journal-title":"International Immunopharmacology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1060","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/jgh.13853","article-title":"Honokiol attenuates diet-induced non-alcoholic steatohepatitis by regulating macrophage polarization through activating peroxisome proliferator-activated receptor gamma","volume":"33","author":"Zhong","year":"2018","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145100","article-title":"PPARgamma enhanced Adiponectin polymerization and trafficking by promoting RUVBL2 expression during adipogenic differentiation","volume":"764","author":"Zhu","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1070","doi-asserted-by":"crossref","first-page":"26817","DOI":"10.1016\/S0021-9258(19)74184-2","article-title":"Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver","volume":"268","author":"Zhu","year":"1993","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00005-008-0037-y","article-title":"Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma","volume":"56","author":"Zieleniak","year":"2008","journal-title":"Archivum Immunologiae et Therapiae Experimentalis (Warsz)"},{"key":"10.1016\/j.pharmthera.2023.108391_bb1080","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040365","article-title":"Hepatic stellate cell activation and inactivation in nash-fibrosis-roles as putative treatment targets?","volume":"9","author":"Zisser","year":"2021","journal-title":"Biomedicines"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:02:03Z","timestamp":1778670123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":216,"alternative-id":["S0163725823000554"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108391","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108391"}}